Eravacycline

The clinical treatment of multidrug-resistant bacterial infections has long faced the dilemma of limited available drugs and insufficient efficacy. As a novel fully synthetic fluorocycline antibacterial agent, eravacycline binds to the 30S subunit of bacterial ribosomes, blocks the binding site of aminoacyl-tRNA to ribosomes, and inhibits bacterial protein synthesis. It has broad-spectrum antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and anaerobic bacteria, and particularly maintains potent antibacterial effects against multidrug-resistant strains such as carbapenem-resistant Enterobacteriaceae and methicillin-resistant Staphylococcus aureus. It is clinically mainly used for the treatment of complicated intra-abdominal infections in adults aged 18 years and above, providing a brand-new treatment option for patients with drug-resistant bacterial infections.

The global market size of eravacycline was approximately USD 280 million in 2023, and the compound annual growth rate from 2024 to 2030 is expected to remain at around 12%. The main driving factors for the growth are the rising incidence of global multidrug-resistant bacterial infections and the increased recommendation level of new antibacterial agents in clinical guidelines. At present, the original research product occupies the dominant share in the global market, while the Chinese market is still in the early stage of commercialization. A number of local pharmaceutical companies have deployed the research and development of generic drugs. With the subsequent approval of generic drugs and the advancement of medical insurance negotiations, the accessibility of the product will be significantly improved.

The original research enterprise of eravacycline is Tetraphase Pharmaceuticals, and the original research trade name is Xerava. The expiration date of the core compound patent in the United States is 2029, and the expiration date of the core compound patent in China is 2030. The main dosage form approved for the original research product is injection, with a specification of 50 mg per vial. It has been included in the FDA Reference Listed Drug Catalog, and also included in the China Listed Drug Catalog as a reference listed drug. Up to now, the eravacycline active pharmaceutical ingredients of multiple enterprises in China have obtained A status through CDE registration, and the eravacycline for injection of the original research enterprise and multiple domestic enterprises has been approved for marketing in China. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of eravacycline impurity reference standards. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and provide stable and reliable reference standard support for pharmaceutical enterprises in the whole process of API research and development, quality research and declaration.